IQVIA (NYSE:IQV) Given New $161.00 Price Target at Robert W. Baird

IQVIA (NYSE:IQV) had its target price decreased by Robert W. Baird from $195.00 to $161.00 in a research note released on Wednesday morning,Benzinga reports. Robert W. Baird currently has a neutral rating on the medical research company’s stock.

IQV has been the subject of several other reports. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. UBS Group cut their price target on shares of IQVIA from $255.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday. Citigroup decreased their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Barclays cut their target price on IQVIA from $170.00 to $165.00 and set an “equal weight” rating for the company in a research note on Wednesday. Finally, Hsbc Global Res cut IQVIA from a “strong-buy” rating to a “hold” rating in a report on Friday, April 25th. Eight investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $231.71.

IQVIA Stock Down 2.9 %

IQV stock opened at $148.90 on Wednesday. The company has a market cap of $25.76 billion, a price-to-earnings ratio of 19.85, a PEG ratio of 1.99 and a beta of 1.34. The firm has a 50-day moving average of $163.91 and a two-hundred day moving average of $188.53. IQVIA has a 12 month low of $135.97 and a 12 month high of $252.88. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The firm’s revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the business posted $2.54 earnings per share. As a group, analysts forecast that IQVIA will post 10.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IQV. American National Bank & Trust acquired a new stake in IQVIA in the 1st quarter valued at about $26,000. Synergy Asset Management LLC acquired a new stake in IQVIA in the fourth quarter valued at approximately $33,000. Golden State Wealth Management LLC lifted its stake in IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock worth $31,000 after acquiring an additional 130 shares during the last quarter. AllSquare Wealth Management LLC acquired a new position in IQVIA during the 1st quarter worth approximately $33,000. Finally, ST Germain D J Co. Inc. raised its holdings in shares of IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 76 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.